The FDA approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.
The FDA has granted approval to the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.1
This development enables the identification of patients who may benefit from treatment with zanidatamab and provides a more precise method for determining HER2 status.
The FDA granted accelerated approval to zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2+ biliary tract cancer on November 20, 2024.2 Findings from the phase 2b HERIZON-BTC-01 trial (NCT04466891) supported this approval.
“This test is a step forward in furthering access to personalized medicine,” Jill German, head of the Pathology Lab at Roche Diagnostics, stated in a news release.1 “The prognosis for patients diagnosed with biliary tract cancer is poor, as very few treatment options exist. Now, these patients have access to the first standardized test that could make them eligible for targeted therapy, potentially improving clinical outcomes.”
This marks the first HER2-targeted treatment and companion diagnostic specifically approved by the FDA in this disease state.
HERIZON-BTC-01 enrolled 87 patients with HER2-amplified, locally advanced unresectable or metastatic biliary tract cancer, including gallbladder cancer and intra-/extra-hepatic cholangiocarcinoma. Patients were enrolled if they had received prior gemcitabine-containing therapy, and all patients were required to have centrally confirmed HER2 status on tissue samples.2
The primary end point of the study was confirmed overall response rate (cORR) by independent central review (ICR), and secondary end points were duration of response (DOR), disease control rate (DCR), progression-free survival, overall survival (OS), and safety.3
In cohort 1 of the phase 2b HERIZON-BTC-01 trial, which included 62 patients with HER2+ BTC with a median age of 64 years (range, 38-79), zanidatamab led to an ORR of 52% (95% CI, 39%-65%) and a median DOR of 14.9 months per ICR (95% CI, 7.4-not evaluable). Partial responses were seen in 30 patients and 2 patients had a complete response.2
For safety, the prescribing label for zanidatamab lists that in the 80-patient safety population, adverse events (AEs) occurring in at least 20% of patients were diarrhea, infusion-related reaction, abdominal pain, and fatigue.4 Serious AEs (SAEs) occurred in 53% of patients receiving zanidatamab. The most common SAEs were biliary obstruction (15%), biliary tract infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%), and fatigue (2.5%). In this safety population, 2.5% of patients permanently discontinued zanidatamab due to an AE, and 1 patient treated with zanidatamab had a fatal AE.
HERIZON-BTC-302 (NCT06282575), an ongoing, confirmatory, phase 3 study, is now assessing treatment with zanidatamab plus standard-of-care (SOC) therapy in the frontline vs SOC therapy alone in patients with HER2-positive biliary tract cancer.1
Phase 1b/2 Study of BXQ-350 in Metastatic Colorectal Cancer Completes Enrollment
November 27th 2024Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.
Read More